悪性リンパ腫の治療に関する研究 第1編 化学療法不応例および再発例に対するadriamycin, vincristine, ifosfamideおよびprednisolone併用(AVIP)療法
スポンサーリンク
概要
- 論文の詳細を見る
Fifty-seven patients with advanced malignant lymphoma, who had failed to achieve complete remission or relapsed after conventional combination chemotherapy, were treated with a combination of adriamycin, vincristine, ifosfamide and prednisolone (AVIP). Twenty-five patients were given relatively low doses of adriamycin (0.5mg/kg), vincristine (0.025mg/kg), and ifosfamide (25mg/kg) at 7-day intervals (Regimen I), and the remaining 32 patients were given relatively high doses of these drugs (1.2mg/kg of adriamycin, 50mg/kg of ifosfamide and 0.03mg/kg of vincristine) at 21-day intervals (Regimen Ⅱ). Among 8 patients with Hodgkin's disease, 7 (88%) achieved objective remission including 4 (50%) complete remissions, and 3 complete respondors remain disease free in a follow-up from 44 months to 89 months. The overall median survival was more than 50 months, ranging from 12 months to more than 90 months. Among 49 patients with non-Hodgkin's lymphoma, 32 (65%) achieved objective remission including 15 (31%) complete remissions. The median duration of complete remission was 8 months, and 3 complete respondors remain disease free at 13, 36 and 90 months, respectively. The overall median survival was 8 months, ranging from 2 months to more than 91 months. The diffuse large cell type was the most frequent in non-Hodgkin's lymphoma. Among 27 patients with this histologic type, 17(63%) had objective remission including 7 (26%) complete remissions. The median duration of complete remission and the median survival were 11 months and 8 months, respectively. There were no significant differences in the therapeutic results of Regimen I and Regimen Ⅱ, although the latter showed a slightly higher response rate and longer duration of complete remission in non-Hodgkin's lymphoma. Reversible bone marrow toxicity was the major toxic reaction, but both regimens were well tolerated. These results indicate that a combination of AVIP is useful for treatment of malignant lymphomas refractory to conventional chemotherapy.
- 岡山医学会の論文
- 1986-08-30
著者
関連論文
- 小細胞癌に関する臨床的検討 : 生存期間からみた治療法の評価
- 221 溶血性貧血を伴ったアレルギー性肉芽腫性血管炎の1例
- 第29回日本肺癌学会中国・四国支部会 : 54.両側肺野びまん性陰影を伴った悪性リンパ腫の1例
- 退院後の生活指導--血液疾患--悪性リンパ腫
- 悪性リンパ腫の治療に関する研究 第1編 化学療法不応例および再発例に対するadriamycin, vincristine, ifosfamideおよびprednisolone併用(AVIP)療法
- 悪性リンパ腫の治療に関する研究 第2編 悪性リンパ腫治療における骨髄生検の意義
- 悪性リンパ腫治療の進歩 (実地臨床に役立つ血液の知識)
- 30.肺癌における多剤併用療法 : COMP療法を中心に(第16回日本肺癌学会中国・四国支部会)
- 肺癌に対する多剤併用療法cyclophosphamide, vincristine, methotrexate, procarbazine併用COMP療法の臨床治験